 The availability of RAL provides an opportunity to examine alternative ARV strategies that may be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. Such combinations might include RALATV regimen without a concomitant NtRTIs based backbone andor the inclusion of RTV. However, there is little data available to date regarding such a combination. HIV care providers have already begun to use the combination of RAL unboosted ATV as the patients they care for are intolerant of RTV or have had major side effectstoxicity with NtNRTIs. More investigation is required to determine if RALATV is an efficacious and safe alternative to RTV boosted PI based ARV strategies. Before a RAL based strategy that does not include NtRTIs or RTV can be compared to other ARV class strategies for long-term efficacy outcomes, preliminary data on a RALATV based regimen is needed. This pilot study will provide data on the safety and efficacy of the combination of RAL 400mg BID ATV 300 mg BID in ARV-experienced subjects that have a suppressed HIV viral load on a RTV boosted PI based regimen who are then switched to a regimen of RAL 400mg BID ATV 300mg BID. 